Daiichi Sankyo Reports Interim Data of P-III (DESTINY-Gastric04) Study Evaluating Enhertu in HER2+ Metastatic Gastric Cancer Patients
Shots:
- The data from P-III (DESTINY-Gastric04) study showed statistically significant and clinically meaningful improvement in OS vs ramucirumab & paclitaxel in 2L HER2+ (IHC 3+ or IHC 2+/ISH+) unresectable and/or metastatic gastric or GEJ adenocarcinoma pts.
- The safety profile observed in DESTINY-Gastric04 aligns with Enhertu's established safety record. The company expects to present data from the study at an upcoming medical meeting and share it with global regulatory authorities
- Daiichi Sankyo discovered Enhertu, which is being jointly developed and commercialized by Daiichi Sankyo & AstraZeneca; based on various studies, Enhertu is approved in 65+ countries
Ref: Daiichi Sankyo | Image: Daiichi Sankyo
Related News:- AstraZeneca and Daiichi Sankyo Receive CHMP’s Positive Opinion for Datroway to Treat HR+/HER2- Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
